

**3M**

**Tegaderm™**

IV Care Solutions

**All you need,  
all in one.**



# All you need, all in one.



Every site presents the potential for infection, dislodgement, skin damage, and other complications. You need evidence-based products and protocols to minimize the risks of vascular access complications and help you achieve better patient outcomes.

3M™ Tegaderm™ CHG I.V. Securement Dressing is the only transparent dressing cleared by the FDA and proven to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization that aligns with evidence-based guidelines and practice standards.

- Infection Reduction
- Site Visibility
- Consistent Application
- Catheter Securement





## Infection Reduction

Clinically proven to reduce CRBSIs by 60% in patients with central and arterial lines;<sup>1</sup> is active immediately and maintains consistent levels of antimicrobial activity for 10 days<sup>2</sup>

## Site Visibility

Transparent dressing and gel pad enable early identification of complications at the insertion site

## Consistent Application

The integrated CHG gel pad and dressing are designed to ensure standardized, correct application<sup>3</sup>

## Catheter Securement

Designed to minimize catheter movement and dislodgement

# Inspired by you.


Over the last 35 years clinicians have come to rely on Tegaderm™ transparent film dressings. Since then, we've listened, we've learned, and we've responded.

We've applied science in creative ways to:

- Create dressings that are more comfortable
- Make it easier for clinicians to provide reliable antimicrobial protection
- Ensure catheters stay in place without causing undue pain or distress

**The full line of Tegaderm™ CHG Dressings may be worn up to 7 days and provide:**

- CHG antimicrobial protection
- Secure adhesion
- Gentle removal
- I.V. site visibility
- Breathability
- Patient comfort



## **3M™ Tegaderm™ Chlorhexidine Gluconate (CHG) I.V. Securement Dressing**


The only transparent dressing proven to reduce CRBSI and vascular catheter colonization. The gel pad provides 2% CHG to the skin surface immediately, without requiring moisture to activate. The integrated design ensures consistent application, aligning with evidence-based guidelines and practice standards.

# Clinically proven to reduce CRBSI.

Contaminations are caused by extraluminal sources (bacteria originating on the surface of the skin and growing along the outside of the catheter), by intraluminal sources (bacteria transferred to the hub or connector from environmental factors) with the remaining coming from other sources.<sup>4</sup>

CHG skin preps are used to minimize contamination of the insertion site, but microbes penetrate the skin deeper than the skin preps, and regrowth can occur within 24 hours.

3M™ Tegaderm™ I.V. Securement Dressings protect against extraluminal contamination and are proven to reduce CRBSI and vascular catheter colonization.



# Align your protocols with standards of practice.

The Centers for Disease Control and Prevention (CDC), Infusion Nurses Society (INS), Association for Professionals in Infection Control and Epidemiology (APIC), Society for Healthcare Epidemiology of America (SHEA), and other organizations offer evidence-based best practices to help minimize I.V. site complications. Choose 3M Tegaderm™ CHG I.V. Securement Dressings and be sure you're meeting or exceeding best practices for better patient and economic outcomes.

## Infection Reduction

APIC, INS and the SHEA Compendium recommend CHG-impregnated dressings.<sup>6,7,8</sup> In use for over 50 years, CHG has proven to be an effective antimicrobial. Bacterial resistance to CHG has been rare.<sup>9</sup>

## Site Visibility

The CDC and *Infusion Therapy Standards of Practice* recommend the use of transparent dressings because they permit continuous visual inspection of the catheter site.<sup>6,10</sup>

## Consistent Application

The International Organization of Standards promote the importance of medical device design to support correct use, patient safety, user satisfaction and to reduce medical device-related errors.<sup>11</sup>

## Catheter Securement

The CDC and *Infusion Therapy Standards of Practice* recommend the use of sutureless securement devices to minimize the risks of movement, dislodgement, and needlestick injuries.<sup>6,10</sup>

# Choose the dressing that's right for you.

3M™ Tegaderm™ CHG Dressings come in multiple sizes and shapes to accommodate a variety of sites and central vascular access devices (CVAD).



PICC



Peripheral



Arterial



PICC



Subclavian



Femoral

# See the evidence for yourself.

**Proven to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization<sup>1</sup>**

The indication is based on the results of a randomized, multi-arm, controlled clinical trial consisting of 1,879 subjects with 4,163 central venous and arterial catheters conducted at 11 hospitals that showed the use of Tegaderm™ CHG I.V. Securement Dressing reduced the incidence of CRBSI by 60% in patients with central and arterial lines.


**Offers consistent antimicrobial activity<sup>2</sup>**

Day 1 | ..... Day 10

*in vitro* tests demonstrated that the reservoir of CHG within the gel pad was as available and as effective at Day 10 as Day 1.

**Maintains lower skin organism counts than BIOPATCH® Disk<sup>5</sup>**

Pairwise testing done against Tegaderm™ CHG Dressing using a paired t-test with Holm stepwise adjustment for multiple comparisons.



\* p-values < 0.01. \*\* represents p-values < 0.001. One subject had baseline <2.5 log<sub>10</sub> CFU/cm<sup>2</sup>, one had dressings lost by day 4 and one lost BIOPATCH® by day 7. All pairwise testing done against Tegaderm™ CHG Dressing using a paired t-test with Holm stepwise adjustment for multiple comparisons.




Tegaderm™ CHG I.V. Securement Dressings have been the subject of several clinical studies by leading researchers in infection prevention and infusion therapy. To see more of the evidence supporting the proven performance of Tegaderm™ CHG Dressings, visit [3M.com/TegadermCHG](http://3M.com/TegadermCHG).

**Tegaderm™ CHG I.V. Securement Dressings**

**are designed to ensure consistently correct application<sup>3</sup>**


**Higher Percentage of CHG Applied Correctly**

Tegaderm™ CHG I.V. Securement Dressing



n=120

BIOPATCH® CHG Disk



n=128

Provides a **larger area** of antimicrobial protection



The CHG gel pad's unique size, shape and composition provide a greater area of antimicrobial activity than BIOPATCH® Disk.



**Absorbs blood & fluids<sup>1</sup>**

The CHG gel pad can absorb blood and other fluids without compromising antimicrobial activity.

## **3M™ Tegaderm™ CHG I.V. Securement Dressing Receives FDA 510(k) Clearance for Expanded Indication to Reduce Catheter-Related Bloodstream Infections**

ST. PAUL, MINN. June 6, 2017 – Catheter-related bloodstream infections (CRBSI) are life threatening for patients and costly for the medical professionals and facilities caring for them. 3M is pleased to announce that the U.S. Food and Drug Administration (FDA) has recognized the efficacy of 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing in reducing CRBSI, expanding the product's 510(k) indication to include CRBSI reduction.

The expanded indication is supported by a randomized, multi-arm, controlled clinical trial of 1,879 subjects that found Tegaderm CHG I.V. Securement Dressing reduced CRBSI by 60 percent in patients with central and arterial lines ( $p=0.020$ ).<sup>1</sup>

## **3M™ Tegaderm™ CHG I.V. Securement Dressing meets the new recommendations from the Centers for Disease Control (CDC) for reducing bloodstream infections.**

The Centers for Disease Control (CDC) recently updated its recommendation on use of chlorhexidine-impregnated dressings in its globally-recognized Guidelines for the Prevention of Intravascular Catheter-Related Infections (2011). The new recommendation calls for use of Chlorhexidine-impregnated dressings with an FDA-cleared label that specifies a clinical indication for reducing catheter-related bloodstream infection (CRBSI) or catheter-associated bloodstream infection (CABS) to protect the insertion site of short-term, non-tunneled central venous catheters for patients aged 18 years and older.

3M Tegaderm CHG I.V. Securement Dressing remains the only transparent dressing indicated and proven to reduce CRBSI, aligning with evidence-based guidelines and practice standards. This includes the 2016 Infusion Therapy Standards of Practice recommendation for the use of transparent dressings that permit continuous visual inspection of the catheter site.<sup>2</sup>





The CDC's evidence-based recommendations elevate current best practices in reducing lifethreatening and costly bloodstream infections. The revisions highlight the strong clinical data that supports use of Tegaderm CHG I.V. Securement Dressing worldwide. At 3M, our goal is zero bloodstream infections. We'll keep innovating and educating to make that future possible.

Tegaderm CHG I.V. Securement Dressing meets the CDC's highest evidence-based recommendation category, IA, meaning it is a strong recommendation supported by high-to-moderate quality evidence suggesting net clinical benefits or harms.

<sup>1</sup> Timsit JF et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. *Am J Crit Care Med.* 2012;186(12): 1272-1278  
<http://www.atsjournals.org/doi/pdf/10.1164/rccm.201206-1038OC>.

<sup>2</sup> Infusion Nurses Society (INS). *Infusion Therapy Standards of Practice.* INS; 2016.

# Ordering Information

Product	Product Number	CHG Gel Pad Size	Dressing Size	Suggested Devices
<b>3M™ Tegaderm™ Chlorhexidine Gluconate (CHG) I.V. Securement Dressing</b>				
	1657R	1 ½ in x 1 ¾ in    3 cm x 4 cm	3 ½ in x 4 ½ in    8,5 cm x 11,5 cm	All CVCs, Arterial, Dialysis, Midline and other percutaneous devices
	1658R	1 ½ in x 1 ¾ in    3 cm x 4 cm	4 in x 4 ¾ in    10 cm x 12 cm	Universal, other percutaneous devices
	1659R	1 ½ in x 2 ¼ in    3 cm x 7 cm	4 in x 6 ⅞ in    10 cm x 15,5 cm	All CVCs and PICCs
	1660R	¾ in x ¾ in    2 cm x 2 cm	2 ¾ in x 3 ⅜ in    7 cm x 8,5 cm	PIVs, Midline, Arterial, CVCs and other percutaneous devices

## References

1. Timsit JF et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. *Am J Crit Care Med.* 2012; 186(12): 1272-1278 <http://www.atsjournals.org/doi/pdf/10.1164/rccm.201206-1038OC>.
2. Schwab D. Antimicrobial Activity of a CHG-Impregnated Gel Pad for IV Site Protection. Infusion Nurses Society (INS), May 2008.
3. Kohan C., MT, MS, CIC, Boyce J., MD. American Journal of Infection Control (AJIC); 2013; Vol 41, Issue 6, S142-S143; doi <http://dx.doi.org/10.1016/j.ajic.2013.03.283>
4. Bouza E, Burillo A, Munoz P. Catheter-related infections: diagnosis and intravascular treatment. *Clinical Microbiology and Infection*, 2002; 8(5): 265-274.
5. Bashir MH, Olson LK, Walters SA. Suppression of regrowth of normal skin flora under chlorhexidine gluconate dressings applied to chlorhexidine gluconate-prepped skin. *Am J Infect Control.* 2012; 40(4): 344-8.
6. Centers for Disease Control and Prevention. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011. Available at: <http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf>
7. APIC Implementation Guide: Guide to Preventing Central Line-Associated Bloodstream Infections, Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) 2015.
8. Strategies to Prevent Central Line-Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update. *Infect Control Hosp Epidemiol.* July 2014; Vol 35, No 7.
9. Denton GW. Chlorhexidine. Taken from: Block SS, ed. *Disinfection, Sterilization, and Preservation.* 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001;321-336.
10. Infusion Nurses Society (INS). Infusion Therapy Standards of Practice. INS; 2016.
11. International Electrochemical Commission: IEC 62366-1:2015 Δ IEC 201
12. Olson C, Heilman J. Clinical Performance of a New Transparent Chlorhexidine Gluconate Central Venous Catheter Dressing. *Journal of the Association for Vascular Access.* 2008; March; Vol 13, No 1; 13-19.

To learn more about 3M™ Tegaderm™ CHG Dressings or to schedule a product evaluation, visit us at [3M.com/TegadermCHG](http://3M.com/TegadermCHG), contact your 3M Critical & Chronic Care Solutions representative or call the 3M Health Care Customer Helpline at 1-800-228-3957. Outside of the United States, contact the local 3M subsidiary.

# High five thirty-five



*Clinicians inspired the invention of 3M™ Tegaderm™ dressings. Ever since we introduced the product 35 years ago, we've valued your partnership in continually improving our solutions to help you provide the best care for your patients.*

*Thank you. We couldn't have done it without you.*

**3M.com/tegaderm**

© 3M 2017. All rights reserved. 3M and Tegaderm are trademarks of 3M Company.

**3M**


Health Care

**Critical & Chronic Care Solutions**

3M India Limited  
Concorde Block, UB City,  
24, Vittal Mallya Road,  
Bengaluru - 560 001  
E-mail: 3Mhealthcare.india@mmm.com  
www.3m.com/tegadermchg

3M Health Care  
Helpline **1-800-425-3030**  
TOLL FREE

3M and Tegaderm are trademarks of 3M.  
© 3M 2018.

Visit us on Facebook   
[facebook/3mtegadermivsolutions](https://facebook.com/3mtegadermivsolutions)